Analytical Data
-
Gene name
HLA-A*11:01&B2M Monomer
- Application
-
Alternative Names
HLA-A*1101 & B2M
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAV53343.1 (G25-T305)&P61769
-
Expression Region
AAV53343.1 (G25-T305)&P61769 (I21-M119)
-
Molecular Weight
42-45 kDa and 13 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*11:01 is a major histocompatibility complex (MHC) class I molecule that plays a crucial role in the immune system by presenting peptide antigens to CD8+ T cells. The B2M (beta-2 microglobulin) component is essential for the stable expression of MHC class I molecules on cell surfaces. The combination of HLA-A*11:01 and B2M in a monomeric recombinant protein format has garnered attention in immunological research due to its potential applications in vaccine development, disease diagnostics, and understanding T cell immune responses. The study of this recombinant protein allows for detailed analysis of T cell recognition and activation, which is vital for understanding autoimmune diseases, infectious diseases, and cancer. Furthermore, the structural and functional characterization of HLA-A*11:01&B2M monomers aids in the identification of peptide-binding specificities and can enhance the design of peptide-targeted therapies. Given the increasing prevalence of diseases linked to T cell responses, the development of these recombinant proteins represents a significant advancement in translational immunology, providing a platform for both therapeutic and diagnostic innovations.
